Popular Articles
Natural Remedies

Targeted Cancer Treatment Following Breakthrough In Radiotherapy
Current radiation therapy treatment damages a patient"s healthy tissue as well as eradicating the tumour it is intended to destroy, making the treatment especially invasive and often causing nasty side effects.
generic viagra online
Clotting In Veins Close To Skin May Be Associated With More Dangerous Deep-Vein Blood Clots
About one-fourth of patients with superficial vein thrombosis-clotting in blood vessels close to the skin-also may have the life-threatening condition deep vein thrombosis, according to a report in the July issue of Archives of Dermatology, one of the JAMA/Archives journals.
News of the day
What Are Gallstones? What Causes Gallstones?
Gallstones are lumps or stones that develop in the gallbladder or bile duct. Some of the chemicals which exist in the gallbladder, such as cholesterol, calcium bilirubinate, and calcium carbonate, harden into either one large stone or many small ones. According to Medilexicon"s medical dictionary, a gallstone is "A concretion in the gallbladder or a bile duct, composed chiefly of a mixture of cholesterol, calcium bilirubinate, and calcium carbonate, occasionally as a pure stone composed of just one of these substances". An article describes a gallbladder in the bile duct similar to trying to squeeze a golf ball through a straw.
Public Health

Telemonitoring Systems At Heart Failure Congress 2009

Telemonitoring systems, by which the symptoms of heart failure can be remotely assessed, now provide a strategy for the improved personalised care of patients, according to Professor John Cleland from the University of Hull, UK.1 He told Heart Failure Congress 2009 that the management of heart failure is complex but most effective when tailored to the individual patients" needs and condition.2 "Unfortunately," he added, "the res required to offer this tailored treatment outside a hospital setting are generally not available. Current services provide, at best, only a crude attempt to deliver long-term, personalised healthcare, but telemonitoring provides a strategy which could radically change this situation." Professor Cleland explained that the first generation of home monitoring devices for heart failure were relatively simple. They were designed to measure symptoms, weight, heart rate and rhythm, and blood pressure. But, he said, "from the patient"s perspective, they were relatively unrewarding since the systems provide little in the way of advice or feedback. Nonetheless, a series of randomised controlled trials have shown a reduction in mortality and in days spent in hospital, although not in the rate of hospitalisation." Ongoing trials of second generation equipment, he continued, reflect the same measure of symptom assessment but a more interactive experience for the patient. "These newer systems," he explained, "provide education, feedback to patients on their results, treatment and appointment reminders and a limited amount of advice on adjusting therapy. They are likely to deliver even greater health gains than first generation systems." And now, further generations of telemonitoring systems are being developed, including: * Implanted systems - ranging form a large pacemaker-like device which simply measures cardiac output and filling pressures, to standard pacemakers and defibrillators with additional telemonitoring capability, to devices that can be implanted percutaneously and don"t require batteries. These may or may not be linked to external sensors for measuring weight and blood pressure. * Ingested systems - as an integral part of the patient"s daily therapy * New sensors which can measure heart, lung and vascular function and/or fluid retention more accurately. * New systems which empower the patient, allowing them to make their own decisions about their care, with a distant supervisory role for a nurse or doctor. By including voluntary services and informal carers, this can increase rather decrease social inclusion. However, Professor Cleland added that such a rapid technical evolution has run far ahead of any service evolution, and warned that conventional clinical trials are likely to underestimate the benefits of these new telehealth systems once integrated into an efficient service. Future clinical trials, he said, should ensure service integration and define the "control" intervention: "If service integration is poor or insufficient res are invested in the control group, then even an effective technology will fail." A meta-analysis of 14 randomised controlled trials (4264 patients) of remote monitoring found that programmes for chronic heart failure which included some form of remote monitoring had a positive effect on clinical outcomes in community-dwelling patients with chronic heart failure. Cleland JGF. Assessment of symptoms in clinics and trials. 31 May, 16.00-17.30. Heart Failure Congress 2009 is organised by the European Society of Cardiology and Heart Failure Association of the ESC, and takes place from 30 May to 2 June at the Palais Acropolis, Nice, France. Clark RA, Inglis SC, McAlister FA, Cleland JG, Stewart S. Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis. BMJ 2007; 334: 942. * Information on the scientific programme for Heart Failure Congress 2009 is available at http://spo.escardio.org/Welcome.aspx?eevtid=31 ESC Press Office European Society of Cardiology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):